NASDAQ$NERV
Minerva Neurosciences Inc · Q1 2025 earnings
Q1 2025 earnings · · Before market open · Investor relations
Briefing
Minerva Neurosciences reported first quarter 2025 financial results and business updates
Minerva Neurosciences reported a net loss of $3.8 million for the first quarter of 2025, a significant improvement compared to the $8.6 million net loss in the same period last year. The decrease in net loss was primarily driven by lower research and development expenses and the absence of non-cash interest expense related to the sale of future royalties. The company continues to engage with the FDA regarding the Complete Response Letter for roluperidone.
- Net loss for Q1 2025 was $3.8 million, down from $8.6 million in Q1 2024.
- Research and development expense decreased to $1.4 million in Q1 2025 from $4.2 million in Q1 2024.
- General and administrative expense remained consistent at $2.5 million in both Q1 2025 and Q1 2024.
- Cash, cash equivalents, and restricted cash totaled $17.4 million as of March 31, 2025.
Headline financials
Revenue & EPS history
Minerva Neurosciences · Revenue · Quarterly
$0
Forward guidance
Minerva Neurosciences continues interactions with the FDA to address questions regarding the Complete Response Letter for roluperidone and expects to maintain compliance with Nasdaq listing standards.
Tailwinds
- Continued engagement with FDA to potentially resolve CRL for roluperidone.
- Expectation to maintain Nasdaq listing compliance.
- Focus on developing therapies for CNS diseases.
- Advancement of pipeline candidates like MIN-301 for Parkinson's disease.
- Cash position to support ongoing operations and clinical development plans.
Headwinds
- Uncertainty regarding the outcome and timing of interactions with the FDA.
- Risks associated with regulatory processes.
- General risks of developing biopharmaceutical product candidates.
- Ability to raise additional capital on acceptable terms.
- General economic conditions impacting operations.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2025
-1.6%
Avg return
Earnings day
-3.7%
Avg return
5 days after
+24.7%
Avg return
30 days after
38%
16 / 42 earnings
Positive
+20.6%
Q1 2021
Best reaction
-27.7%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -1.3% | -7.1% | — | |
| Q3 2025 | -3.9% | -2.9% | -2.1% | |
| Q2 2025 | -2.8% | -7.0% | +22.0% | |
| Q1 2025 | -0.1% | -8.0% | +9.4% | |
| Q4 2024 | +0.0% | -6.7% | +1.1% | |
| Q3 2024 | -0.4% | +1.0% | -8.6% | |
| Q2 2024 | +2.1% | +2.9% | -7.5% | |
| Q1 2024 | -0.4% | -0.8% | +8.1% | |
| Q4 2023 | -21.9% | -68.2% | -69.7% | |
| Q3 2023 | -3.0% | -24.1% | +10.5% | |
| Q2 2023 | +10.6% | +2.0% | -12.0% | |
| Q1 2023 | -22.4% | -7.7% | +3.4% | |
| Q4 2022 | -10.8% | -15.1% | -19.5% | |
| Q3 2022 | +13.3% | +2.2% | +3.8% | |
| Q2 2022 | -27.7% | -30.4% | +123.0% | |
| Q1 2022 | +1.0% | -16.2% | -18.6% | |
| Q4 2021 | +0.5% | -5.1% | +17.6% | |
| Q3 2021 | +8.1% | -3.0% | -28.4% | |
| Q2 2021 | -3.8% | -0.5% | -3.3% | |
| Q1 2021 | +20.6% | +48.7% | +936.6% | |
| Q4 2020 | +8.7% | +16.8% | -7.7% | |
| Q3 2020 | -2.8% | +7.5% | -14.3% | |
| Q2 2020 | +7.9% | +3.0% | -9.6% | |
| Q1 2020 | +1.5% | +22.4% | -58.1% | |
| Q4 2019 | -13.9% | -25.1% | -32.1% | |
| Q3 2019 | +5.8% | +14.1% | +33.1% | |
| Q2 2019 | +4.3% | +6.0% | +12.9% | |
| Q1 2019 | -9.0% | -8.8% | -34.0% | |
| Q4 2018 | -1.1% | +1.4% | -9.1% | |
| Q3 2018 | -16.9% | -18.4% | -33.2% | |
| Q2 2018 | -0.6% | -0.6% | +30.8% | |
| Q1 2018 | -8.8% | -10.3% | +29.4% | |
| Q4 2017 | +12.2% | +9.6% | +20.9% | |
| Q3 2017 | -10.0% | -13.3% | -13.3% | |
| Q2 2017 | -1.5% | +0.0% | -3.7% | |
| Q1 2017 | -2.2% | +0.7% | +47.4% | |
| Q4 2016 | -2.3% | -6.3% | -16.7% | |
| Q3 2016 | -8.1% | -4.1% | +18.6% | |
| Q2 2016 | +6.3% | +5.8% | +10.3% | |
| Q1 2016 | +8.2% | — | — | |
| Q4 2015 | +3.7% | — | — | |
| Q2 2014 | -4.5% | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro